KRAS and colorectal carcinoma: Of note, mutations in KRAS codon 12 or 13 (exon 2) are considered as a major driving force in contributing oncogenic potential to KRAS, as evidenced by the fact that these mutations constitute almost 90% of all KRAS mutations in CRC [18,30–32].